People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pandion Therapeutics Holdco LLC | — | Biotechnology | Series B | $40.0M | $1.6B | 2020 |
Daniel L. Becker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel L. Becker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alan L. Crane | 1 | 3 |
| Rahul Kakkar | 1 | 3 |
| Jill L. Carroll | 1 | 2 |
| Christopher L. Fuglesang | 1 | 1 |
| Carlo L. Rizzuto | 1 | 1 |
| Nancy L. Stagliano | 1 | 1 |
| Donald L. Frail | 1 | 1 |
| Mitchell L. Mutz | 1 | 1 |
| Vikas L. Goyal | 1 | 1 |
| Jo L. Viney | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.